Akorn (AKRX) Given a $9.00 Price Target by Royal Bank of Canada Analysts
Several other equities research analysts have also recently commented on AKRX. Piper Jaffray Companies set a $5.00 price target on shares of Akorn and gave the stock a hold rating in a research report on Tuesday, October 2nd. BidaskClub upgraded shares of Akorn from a buy rating to a strong-buy rating in a research report on Thursday, September 6th. ValuEngine upgraded shares of Akorn from a sell rating to a hold rating in a research report on Tuesday, October 2nd. Craig Hallum upgraded shares of Akorn from a hold rating to a buy rating in a research report on Thursday, October 4th. Finally, Zacks Investment Research upgraded shares of Akorn from a hold rating to a buy rating and set a $16.00 price target on the stock in a research report on Monday, August 27th. Four equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of Buy and an average target price of $14.67.
Shares of NASDAQ AKRX traded down $0.02 during midday trading on Wednesday, reaching $6.85. 2,929,630 shares of the company traded hands, compared to its average volume of 4,226,315. Akorn has a 52 week low of $5.25 and a 52 week high of $33.63. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.87 and a current ratio of 3.47.
Akorn Company Profile
Akorn, Inc, a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health.
Recommended Story: Understanding Market Liquidity
Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.